Definium Therapeutics, Inc.
DFTX · XNASCIK 1813814fmd_17RWT5RZF9KR05ET26EX92D0KGManufacturing · Medicinal Chemicals & Botanical ProductsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 25 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Net interest income | – | (0) | (0) | 1 | 5 | – | – |
| Research and development | – | 19 | 35 | 36 | 52 | 65 | 118 |
| Total operating expenses | – | 33 | 94 | 66 | 94 | 104 | 166 |
| Operating income | – | (33) | (94) | (66) | (94) | (104) | (166) |
| Interest expense | – | – | – | – | 1 | 2 | 5 |
| Interest and investment income | – | – | – | – | 6 | 12 | 11 |
| Other non-operating income (expense) | – | (1) | (0) | 10 | (2) | (5) | (17) |
| Income before taxes | (11) | (34) | (94) | (57) | (96) | (109) | (184) |
| Income tax expense | – | – | (1) | – | – | – | 0 |
| Net income from continuing operations | – | – | (93) | – | – | – | (184) |
| Net income | – | (34) | (93) | (57) | (96) | (109) | (184) |
| Net income to common shareholders | – | – | – | – | – | (109) | (184) |